What is HC Wainwright’s Estimate for NRSN FY2026 Earnings?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) – Research analysts at HC Wainwright boosted their FY2026 EPS estimates for NeuroSense Therapeutics in a note issued to investors on Monday, September 28th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the company will post earnings per share of ($4.45) for the year, up from their previous forecast of ($7.40). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for NeuroSense Therapeutics’ current full-year earnings is ($7.60) per share. HC Wainwright also issued estimates for NeuroSense Therapeutics’ FY2027 earnings at ($7.12) EPS, FY2028 earnings at ($7.58) EPS, FY2029 earnings at ($6.63) EPS and FY2030 earnings at $7.49 EPS.

Separately, Weiss Ratings cut NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $170.00.

NeuroSense Therapeutics Stock Performance

NASDAQ:NRSN opened at $4.78 on Wednesday. The firm’s fifty day moving average is $8.57 and its two-hundred day moving average is $12.95. The firm has a market cap of $9.08 million, a price-to-earnings ratio of -0.44 and a beta of 1.60. NeuroSense Therapeutics has a one year low of $4.36 and a one year high of $26.64.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned approximately 0.21% of NeuroSense Therapeutics as of its most recent SEC filing. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.